Farhad Sedarati

1.7k total citations
36 papers, 1.2k citations indexed

About

Farhad Sedarati is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Farhad Sedarati has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Hematology. Recurrent topics in Farhad Sedarati's work include Ubiquitin and proteasome pathways (11 papers), Protein Degradation and Inhibitors (9 papers) and Acute Myeloid Leukemia Research (7 papers). Farhad Sedarati is often cited by papers focused on Ubiquitin and proteasome pathways (11 papers), Protein Degradation and Inhibitors (9 papers) and Acute Myeloid Leukemia Research (7 papers). Farhad Sedarati collaborates with scholars based in United States, United Kingdom and Japan. Farhad Sedarati's co-authors include J G Stevens, Todd P. Margolis, A.T. Dobson, Jack G. Stevens, Lawrence T. Feldman, Hélène M. Faessel, Ronan Swords, Harry P. Erba, Douglas V. Faller and Michael B. Maris and has published in prestigious journals such as Science, Neuron and Journal of Clinical Oncology.

In The Last Decade

Farhad Sedarati

36 papers receiving 1.2k citations

Peers

Countries citing papers authored by Farhad Sedarati

Since Specialization

Citations

This map shows the geographic impact of Farhad Sedarati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farhad Sedarati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farhad Sedarati more than expected).

Fields of papers citing papers by Farhad Sedarati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farhad Sedarati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farhad Sedarati. The network helps show where Farhad Sedarati may publish in the future.

Co-authorship network of co-authors of Farhad Sedarati

This figure shows the co-authorship network connecting the top 25 collaborators of Farhad Sedarati. A scholar is included among the top collaborators of Farhad Sedarati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farhad Sedarati. Farhad Sedarati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia 2024 ·Leukemia & lymphoma ·Nicholas J. Short, Agnieszka Wierzbowska, Thomas Cluzeau, (unknown), (unknown), Jarosław Czyż, (unknown), Lionel Adès, (unknown), Maël Heiblig, (unknown), Ewa Zarzycka, Shuli Li, (unknown), Tammie C. Yeh, Douglas V. Faller, Farhad Sedarati, Cristina Papayannidis	1
2	A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer 2023 ·Gynecologic Oncology ·Sileny Han, Amit M. Oza, Nicoletta Colombo, Ana Oaknin, Francesco Raspagliesi, Robert M. Wenham, Elena Ioana Braicu, Andrea Jewell, Vicky Makker, Jonathan Krell, Eva María Guerra Alia, Jean‐François Baurain, Zhenqiang Su, Rachel Neuwirth, Sylvie Vincent, Farhad Sedarati, Douglas V. Faller, Giovanni Scambia	7
3	Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors 2022 ·Investigational New Drugs ·Xiaofei Zhou, Ulka N. Vaishampayan, Devalingam Mahalingam, R. Donald Harvey, Ki Y. Chung, Farhad Sedarati, (unknown), Douglas V. Faller, Karthik Venkatakrishnan, Neeraj Gupta	7
4	Metabolism and Disposition of [14C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors 2022 ·Drug Metabolism and Disposition ·Jayaprakasam Bolleddula, Hao Chen, Lawrence H. Cohen, Xiaofei Zhou, (unknown), Allison Berger, Farhad Sedarati, Karthik Venkatakrishnan, Swapan K. Chowdhury	4
5	A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies 2021 ·Targeted Oncology ·Toshio Shimizu, Yasutoshi Kuboki, Chia‐Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V. Faller, (unknown), Neeraj Gupta, Farhad Sedarati, Kyu‐pyo Kim	5
6	Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors 2020 ·Investigational New Drugs ·Xiaofei Zhou, Farhad Sedarati, Douglas V. Faller, Dan Zhao, Hélène M. Faessel, Swapan K. Chowdhury, Jayaprakasam Bolleddula, (unknown), Karthik Venkatakrishnan, Zsuzsanna Pápai	19
7	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer 2020 ·British Journal of Cancer ·Martin H. Voss, Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla, David C. Smith, Andrés Cervantes, Igor Puzanov, Роберто Пили, Ding Wang, Shadia I. Jalal, Shubham Pant, Manish R. Patel, Rachel Neuwirth, (unknown), Yaping Shou, Farhad Sedarati, Douglas V. Faller, Howard A. Burris	67
8	Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours 2019 ·British Journal of Clinical Pharmacology ·Hélène M. Faessel, John Nemunaitis, Todd M. Bauer, A. Craig Lockhart, Douglas V. Faller, Farhad Sedarati, Xiaofei Zhou, Karthik Venkatakrishnan, R. Donald Harvey	15
9	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML 2018 ·Blood ·Ronan Swords, Steven Coutré, Michael B. Maris, Joshua F. Zeidner, James M. Foran, José C. Cruz, Harry P. Erba, Jesús G. Berdeja, Wayne Tam, Saran Vardhanabhuti, (unknown), Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, (unknown), Douglas V. Faller, Michael R. Savona	157
10	Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors 2018 ·Investigational New Drugs ·A. Craig Lockhart, Todd M. Bauer, Charu Aggarwal, Carrie B. Lee, R. Donald Harvey, Roger B. Cohen, Farhad Sedarati, (unknown), Hélène M. Faessel, Ajeeta B. Dash, Bruce J. Dezube, Douglas V. Faller, Afshin Dowlati	62
11	Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes 2017 ·Blood Cancer Journal ·Ronan Swords, Justin M. Watts, Harry P. Erba, Jessica K. Altman, Michael B. Maris, Faiz Anwer, (unknown), H. Stein, Hélène M. Faessel, Farhad Sedarati, Bruce J. Dezube, Francis J. Giles, Bruno C. Medeiros, Daniel J. DeAngelo	28
12	Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML) 2016 ·Blood ·Ronan Swords, Steven Coutré, Michael B. Maris, Joshua F. Zeidner, James M. Foran, José C. Cruz, Harry P. Erba, Jesús G. Berdeja, Wayne Tam, Saran Vardhanabhuti, (unknown), Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Michael R. Savona	7
13	Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study 2009 ·Clinical Therapeutics ·Ronald Emkey, Pierre D. Delmas, Michael A. Bolognese, João Lindolfo Cunha Borges, Felicia Cosman, Sergio Ragi-Eis, Christopher Recknor, Cristiano A. F. Zerbini, (unknown), Farhad Sedarati, Solomon Epstein	26
14	Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss 2008 ·Bone ·Michael R. McClung, Michael A. Bolognese, Farhad Sedarati, Robert R. Recker, Paul D. Miller	26
15	Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension 2008 ·Clinical Rheumatology ·J. A. Stakkestad, P. Lakatos, R Lorenc, Farhad Sedarati, (unknown), Jean‐Yves Reginster	32
16	Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study 2007 ·Current Medical Research and Opinion ·Paul D. Miller, Sol Epstein, Farhad Sedarati, Jean‐Yves Reginster	59
17	Concurrent cetuximab, cisplatin, and radiotherapy (RT) for loco-regionally advanced squamous cell carcinoma of the head and neck (SCCHN): Updated results of a novel combined modality paradigm 2005 ·Journal of Clinical Oncology ·Yan-Ye Su, Dennis H. Kraus, Michael J. Zeléfsky, Eric Lis, Suzanne L. Wolden, (unknown), Farhad Sedarati, Ashok R. Shaha, Jatin P. Shah, David G. Pfister	6
18	Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis C 2003 ·Journal of Hepatology ·Stefan Zeuzem, E. Jenny Heathcote, Mitchell L. Shiffman, Teresa L. Wright, Vincent G. Bain, Morris Sherman, S.V. Feinman, Michael Fried, J. Rasenack, Christoph Sarrazin, Donald M. Jensen, Amy Lin, Joseph H. Hoffman, Farhad Sedarati	47
19	A latent, nonpathogenic HSV-1-derived vector stably expresses β-galactosidase in mouse neurons 1990 ·Neuron ·A.T. Dobson, Todd P. Margolis, Farhad Sedarati, Jack G. Stevens, Lawrence T. Feldman	196
20	Biological Basis for Virulence of Three Strains of Herpes Simplex Virus Type 1 1987 ·Journal of General Virology ·Farhad Sedarati, J G Stevens	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact